FERNAND GOBEIL JR

Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers

Challenge: G protein-coupled receptors (GPCRs) represent attractive biomarkers and therapeutic target classes in cancer research because their aberrant expression and activity are closely correlated with different stages of tumour initiation and progression. The development of small molecule anticancer drugs targeting GPCRs has so far proven to be quite challenging. Thus, there remains a need to identify new approaches to treating … Read More

*MATHIEU PERRÉE

Integrating Functional and Genomic Profiling for Optimal Combination Therapies for Cancer Patients

Challenge: In recent years, a growing number of cancer patients have been treated with therapies targeting specific genetic alterations present in their tumors. Generally, this is done in combination with traditional chemotherapeutic agents that represent the standard of care. However, a systematic analysis to identify the most appropriate combination of chemo and targeted therapy to which a patient will favorably … Read More

JEFF WRANA

qTAP, a novel platform for personalized medicine in cancer

  Competition: CQDM / CIHR Program 2014 Funding: $1,030,000 / 2 years Beginning: July 2015 In the last decade, cancer genomics studies have led to the remarkable revelation that cancer is a much broader and complex disease then initially thought. In parallel, dramatic advances in our ability to design drugs against cancer have created an extensive toolbox of therapeutics. The use of … Read More

MORAG PARK

Integrated tumour-microenvironment biomarkers for improved targeting of breast cancer therapy

  Competition: FOCUS Program 2011 Funding: $1,300,0003 years Début : September 2011 The aim of this project is to develop enabling tools for better stratification of breast cancer patients by integrating information from the tumor and the surrounding stromal tissu. This will allow the development of personalized therapies relevant to specific tumor subtypes. The genetic heterogeneity of breast cancer tumors … Read More

*RICHARD KREMER

Plateforme pour l’enrichissement des cellules tumorales circulantes (CTC) pour la caractérisation et la sensibilité à des médicaments anticancéreux

  Competition: EXPLORE Program 2012 Funding: $300,000 / 2 years (COMPLETED PROJECT) The major challenge in cancer therapy is to stop its progression to more advanced stages (metastasis) where the disease becomes resistant to most forms of therapeutic interventions. Understanding the mechanisms leading to metastasis is only beginning to emerge and is key to develop specific therapeutic interventions. Another complicating … Read More

*YVES ST-PIERRE

Dimer Interference: A novel Approach to Develop Galectin-7-Specific Inhibitors to treat Triple-Negative Breast Cancer

Challenge: Galectins are a family of lectin proteins implicated in tumor progression and immune evasion. When produced in excess by cancer cells, galectins can form homodimers and bind glycans on the surface of T cells. This suppresses the local and systemic immune response in patients, helping tumors to escape immune surveillance and limiting the efficacy of immuno-oncology treatments. To date, … Read More

*ANNE-MARIE MES-MASSON

Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform

  Competition: EXPLORE Program 2012 Funding: $300,000 / 2 years Beginning: September 2014 (COMPLETED PROJECT) Ovarian cancer is a leading cause of cancer deaths in women. Only a portion of women diagnosed with this cancer will respond to conventional drugs, and alternative therapies only work in some cases. In order to better tailor treatment, personalized medicine has turned to ‘markers’ … Read More

*DANIEL CHELSKY

Identification of new biomarkers for neuroendocrine cancers

  Competition: Quantum Leap Québec –  France 2010 Funding: $1,160,000 / 3 years Début : September 2014 (COMPLETED PROJECT) This project will investigate the mechanisms resulting in hypersecretion by neuroendocrine tumors, as well as identify the changes to the proteins secreted by such tumors. Identified candidate targets for modulation of hypersecretion could generate improved therapies. Furthermore, the resulting identification of … Read More

*GORDON SHORE

Integrated platform to identify synthetic lethality opportunities in cancer therapy

  Competition: FOCUS Program 2010 Funding: $2,000,000 / 3 years Beginning: Septembre 2010 (COMPLETED PROJECT) The proposed platform will allow the identification of cellular pathways and gene targets acting in synergy with new or existing drugs for cancer therapy. This platform could also generate novel biomarkers to predict treatment response through personalized medicine. In recent years, only 8% of new … Read More

RICHARD MARTEL

A novel Raman-based multiplex imaging platform for breast cancer biomarkers

  Competition: SynergiQc 2016 Funding: $1,037,155 / 2 years Beginning: April 2017 Challenge: Extensive characterization of tumors is central to the development of personalized therapies such as immunotherapy, now considered one of the most promising and innovative approaches to treatments in the fight against cancer. The capability to detect a multitude of biomarkers simultaneously on the same tissue section would therefore … Read More